What do systematic reviews say?

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ adults (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.23 [0.82, 1.85]
  6 studies · 628 participants
  Moderate

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in adverse drug reactions compared with inpatients ‐ children (low certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.9 [0.61, 5.98]
  2 studies · 156 participants
  Low

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 268 participants
  Moderate

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 119 participants
  Low

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 305 participants
  Low

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.04 [0.29, 3.71]
  6 studies · 628 participants
  Moderate

Outpatient vs inpatients ‐ adults

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 169 participants
  Low

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in adverse drugs reactions compared with inpatients ‐ adults (low certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 8.39 [0.38, 187.15]
  3 studies · 375 participants
  Low

Outpatient vs inpatients ‐ adults

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 169 participants
  Low

Outpatient vs inpatients ‐ adults

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 251 participants
  Low

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ children (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.04 [0.55, 1.99]
  4 studies · 366 participants
  Moderate

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 0.63 [0.15, 2.7]
  3 studies · 329 participants
  Moderate

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 305 participants
  Low